Hyperosmolar hyperglycemic state medical therapy

Hyperosmolar hyperglycemic state Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hyperosmolar hyperglycemic state from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic study of choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hyperosmolar hyperglycemic state medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hyperosmolar hyperglycemic state medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hyperosmolar hyperglycemic state medical therapy
CDC on Hyperosmolar hyperglycemic state medical therapy
Hyperosmolar hyperglycemic state medical therapy in the news
Blogs on Hyperosmolar hyperglycemic state medical therapy
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Hyperosmolar hyperglycemic state medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Husnain Shaukat, M.D [2] Hibatullah Abdul Aleem, M.B.B.S[3]

Overview

Hyperosmolar hyperglycemic state (HHS) is a medical emergency and acute complication of diabetes mellitus that requires prompt treatment. The mainstay of therapy for HHS is intravenous fluid resuscitation, which is the primary initial treatment; insulin is a delayed, low-dose adjunct, with potassium and other electrolyte replacement, correction of hyperosmolality at controlled rates, venous thromboembolism prophylaxis, and treatment of the precipitating cause.

Medical Therapy

Hyperosmolar hyperglycemic state is a medical emergency, generally managed in an ICU or high-dependency setting because of high mortality and monitoring intensity. The therapeutic priorities differ from diabetic ketoacidosis: volume deficits are far larger (~100–200 mL/kg, ~12–15% of body weight), the state is hyperosmolar rather than acidotic, and fluids, not insulin, are the primary initial therapy. Management goals are restoration of circulatory volume and tissue perfusion, gradual correction of hyperosmolality and hyperglycemia, repletion of electrolyte deficits, and identification and treatment of the precipitating cause, with close monitoring for iatrogenic complications.

General principles and monitoring

• Capillary/point-of-care glucose every 1-2 h.
• Serum electrolytes, glucose, creatinine, and serum osmolality every 4 h.
• Continuous cardiac monitoring, strict fluid input/output, and serial neurologic assessment.

Fluid therapy (first-line)

Fluid resuscitation restores intravascular volume, improves renal and tissue perfusion, and lowers glucose and osmolality independent of insulin; glucose falls ~50-70 mg/dL/h (2.8-3.9 mmol/L/h) with fluids alone.

• ADA/EASD: isotonic saline (0.9% NaCl) or a balanced crystalloid (Ringer's lactate, Plasma-Lyte) at 500-1000 mL/h for the first 2-4 h in patients without renal or cardiac compromise. The 2024 consensus newly endorses balanced crystalloids based on observational data showing faster resolution, shorter length of stay, and less hyperchloremic metabolic acidosis than large-volume 0.9% saline.
• JBDS: replace ~50% of the estimated fluid loss within the first 12 h, remainder over the following 12h (a deliberately more cautious approach).
• Subsequent fluids are guided by hemodynamics, hydration status, urine output, and corrected serum sodium. If corrected sodium is normal/high and osmolality is not falling despite adequate positive fluid balance, switch to 0.45% NaCl.
• An initial rise in measured sodium as glucose falls (≈1.6 mmol/L per 100 mg/dL glucose decrease) is expected and is not itself an indication for hypotonic fluid.
• Correct the overall deficit over 24-48 h; use caution in older adults and in heart or kidney disease to avoid iatrogenic fluid overload.
• Add dextrose (5-10%) once glucose reaches ~250-300 mg/dL to permit continued insulin while avoiding hypoglycemia until hyperosmolality resolves.

Safe rates of correction

To minimize the risk of cerebral edema and osmotic demyelination:

Parameter	Maximum rate of correction
Glucose	≤90-120 mg/dL/h (5-6.7 mmol/L/h); expected correction over 8-10 h
Serum sodium	Decline ≤10 mmol/L per 24 h
Osmolality	ADA/Diabetes Canada: <3 mOsm/kg/h; JBDS: 3-8 mOsm/kg/h

Insulin therapy (adjunct, not first-line in pure HHS)

The key modern shift from legacy teaching is that insulin is secondary to fluids in HHS and is started later and at a lower dose than in DKA.

• Start fixed-rate insulin at 0.05 units/kg/h once glucose concentrations stop declining with fluid resuscitation, in the setting of no ketonemia or only mild/moderate ketonemia and no acidosis (ADA/EASD; JBDS titrates up by ~1 unit/h as needed).
• An initial insulin bolus is not recommended in HHS.
• Rapid-acting subcutaneous insulin analog protocols are not recommended for HHS (acceptable only for mild/moderate DKA).
• Once glucose reaches ~250-300 mg/dL, reduce the infusion (e.g., 0.02-0.05 units/kg/h) and add dextrose to keep glucose ~200-300 mg/dL until osmolality and mental status normalize.
• Insulin must never precede volume resuscitation or correction of hypokalemia, because premature insulin shifts water and potassium intracellularly, worsening hypovolemia/hypotension and precipitating dangerous hypokalemia.

Potassium replacement

Total-body potassium is depleted (3-6 mmol/kg) despite frequently normal or high presenting serum levels; insulin and volume expansion drive potassium intracellularly and into the urine.

• K⁺ <3.5 mmol/L: hold insulin; replace at ~10 mmol/h until K⁺ >3.5 mmol/L.
• K⁺ 3.5–5.0 mmol/L: add 20–30 mmol KCl per liter of IV fluid; target 4–5 mmol/L.
• K⁺ >5.0 mmol/L: no potassium; recheck every 2 h.
• Check potassium 2 h after starting insulin, then every 4 h. Severe hypokalemia (≤2.5 mmol/L) during treatment is associated with a ~3-fold increase in mortality.

Other electrolytes

• Phosphate: routine replacement is not beneficial and risks hypocalcemia. Reserve for serum phosphate <1.0 mg/dL with cardiac dysfunction, respiratory depression, anemia, or skeletal-muscle weakness; a 50:50 potassium phosphate/potassium chloride mix limits hypocalcemia.
• Magnesium: often depleted; replace if hypomagnesemia contributes to hypocalcemia or refractory hypokalemia.
• Bicarbonate: no role in HHS (no significant acidosis to correct); it also increases the risk of hypokalemia.

Thromboprophylaxis

Hyperosmolarity confers markedly increased venous thromboembolism (VTE) risk.

• Pharmacologic VTE prophylaxis is warranted in the absence of contraindications; central venous catheters are particularly thrombogenic.
• No trial has demonstrated a mortality/morbidity benefit of prophylaxis specifically in HHS.

Identify and treat the precipitant

Infection is the most common precipitant. Obtain a targeted infectious workup (CBC, inflammatory markers, blood cultures, respiratory viral panel, clinically directed imaging) and treat empirically after cultures when sepsis is suspected. Also evaluate for myocardial infarction, stroke, medication effects (including SGLT2 inhibitors, glucocorticoids), and non-adherence. Monitor for HHS-specific complications, particularly rhabdomyolysis (serial creatine kinase) and thromboembolism.

Criteria for resolution

There is no universally agreed definition. ADA/EASD consider HHS resolved when:

• Measured or calculated serum osmolality <300 mOsm/kg,
• Hyperglycemia corrected (blood glucose <250 mg/dL / 13.9 mmol/L),
• Urine output >0.5 mL/kg/h, and
• Improved cognitive status.

Transition to subcutaneous insulin

• Transition when the patient is alert, hyperosmolality has resolved, and oral intake is tolerated.
• Overlap subcutaneous and IV insulin by 1-2 h (basal insulin ideally given 2-4 h before stopping the infusion), because IV regular insulin has a half-life <10 min and abrupt cessation risks rebound hyperglycemia.
• Estimate total daily dose: 0.5-0.6 U/kg/day in insulin-naive patients, or ~0.3 U/kg/day where hypoglycemia risk is high (kidney failure, frailty). Patients with known diabetes generally resume their prior regimen unless baseline control was inadequate.
• Basal-bolus analog regimens are preferred over NPH/regular human insulin (lower hypoglycemia rates).
• Discharge planning must include education on recognition and prevention of recurrence.

Treatment algorithm

Confirmed HHS (medical emergency; ICU/HDU)

Fluids (first-line)

Insulin (adjunct)

Potassium

0.9% NaCl or balanced crystalloid 500–1000 mL/h × 2–4 h

Start 0.05 U/kg/h only once glucose stops falling on fluids (no bolus)

Check K⁺; guides insulin timing

Guide by corrected Na⁺; switch to 0.45% NaCl if Na⁺ normal/high and osmolality not falling

Reduce to 0.02–0.05 U/kg/h at glucose ~250–300 mg/dL

K⁺ <3.5: hold insulin, replace 10 mmol/h

K⁺ 3.5–5.0: 20–30 mmol KCl/L, target 4–5

K⁺ >5.0: no K⁺, recheck 2 h

Add 5–10% dextrose at glucose ~250–300 mg/dL

Continue until osmolality and mental status normalize

Correction limits: glucose ≤90–120 mg/dL/h; Na⁺ ≤10 mmol/L/24 h; osmolality 3–8 mOsm/kg/h

Also: VTE prophylaxis; treat precipitant; then overlap SC insulin 1–2 h at resolution

Abbreviations: HHS = hyperosmolar hyperglycemic state; ICU = intensive care unit; HDU = high-dependency unit; NaCl = sodium chloride; Na⁺ = sodium; K⁺ = potassium; KCl = potassium chloride; VTE = venous thromboembolism; SC = subcutaneous.